On Monday shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) closed at $63.89. On 23 April, Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) announced positive data from an investigator-sponsored study on triheptanoin, which is being developed for the treatment of movement disorders associated with glucose transporter type-1 deficiency syndrome (Glut1 DS).
Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) in last trading activity moved down -2.88% to close at $1.35. Company weekly performance is -4.26%. Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) is -32.50% away from its 52 week high. Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) declared the presentation of data from preclinical studies demonstrating the combination of phosphatidylserine (PS) blockade with anti-PD-1 or anti-CTLA-4 immune checkpoint inhibitors promoted strong, localized and improved efficacy in models of melanoma and breast cancer.
On Monday shares of Boston Scientific Corporation (NYSE:BSX) closed at $17.98. Company’s sales growth for last 5 years was -2.10% and EPS growth for next 5 years is recorded as 10.00%. Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Deutsche Bank 40th Annual Healthcare Conference on May 6 in Boston.
Robert Half International Inc. (NYSE:RHI) has 3.20% insider ownership while its institutional ownership stands at 88.80%. In last trading activity company’s stock closed at $56.23. On 24 April, Professional staffing firm Robert Half International Inc. (NYSE:RHI) reported revenue rose 11.2% in the first quarter to $1.21 billion, with growth rates the strongest in its US operations.
On last trading day Medivation, Inc. (NASDAQ:MDVN) moved down -3.35% to close at $126.62. Its volatility for the week is 3.03% while volatility for the month is 3.31%. MDVN’s sales growth for past 5 years was 59.30% and its EPS growth for past 5 years was 42.20%. Medivation, Inc. (NASDAQ:MDVN) monthly performance is -1.37%.Credit Suisse Group AG reissued their neutral rating on shares of Medivation Inc. (NASDAQ:MDVN) in a research report sent to investors on Monday morning.